羟嗪亚胺市场 - 增长、趋势、COVID-19 影响和预测 (2023 - 2028)

羟嗪亚胺市场按剂型(片剂、胶囊剂、注射剂、糖浆)、适应症类型和地理位置细分。

羟嗪亚胺市场快照

Hydroxyzine Imine Market
Study Period: 2018 - 2026
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.1 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and it's growth?

市场概况

预计全球羟嗪亚胺市场在预测期内的复合年增长率接近 5.1%。过敏反应人口的增加以及老年人口是预计引发市场增长的主要趋势之一。根据药物数据库统计,羟嗪是前 100 个品牌之一,在美国(2017 年)开了大约 800 万张处方,这也推动了市场增长。此外,随着对开发新型治疗药物研发投资的增加,技术进步也将推动市场增长。据估计,发达地区对疾病汇款疗法的认识提高和医疗保健支出增加将促进收入增长。然而,与这种药物相关的副作用,如头晕、皮疹、

报告范围

以 Atarax 品牌销售的羟嗪亚胺属于一组称为抗组胺药的药物,用于治疗过敏反应。它用于成人和儿童,以减少由荨麻疹(荨麻疹)和皮炎(湿疹)引起的瘙痒。Atarax 也用于治疗成人的焦虑症。

By Dosage Form
Tablets
Capsules
Injection
Syrup
By Indication Type
Histamine-Mediated Pruritus
Urticaria
Atopic Contact Dermatoses
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

胶囊部门预计将在羟嗪亚胺市场占有重要的市场份额

胶囊部分预计将贡献显着的市场份额,归因于易于管理、易于使用、易于获得并广泛用于过敏反应患者。此外,由于羟嗪亚胺减弱中枢神经系统的活动,这些特性有助于羟嗪亚胺治疗与精神神经症相关的焦虑。这导致采用羟嗪亚胺胶囊具有多种优势,例如在不同温度和湿度范围内的稳定性、物理稳定性、低吸湿性和低水分含量,从而促进了细分市场的增长。

Hydroxyzine Imine Market

北美预计将在市场上占有重要份额,预计在预测期内也将如此

北美处于该地区增长的最前沿,也是全球舞台上重要的收入贡献者。越来越多的老年人口和越来越多的过敏患者,高昂的公共和私人医疗保健支出正在刺激该地区的增长。根据疾病控制和预防中心的数据,每年估计有 5000 万美国人患有过敏症,而过敏症是美国慢性病的第 6 大主要原因,因此促进了该地区的收入增长。

Hydroxyzine Imine Market

竞争格局

羟胺市场竞争适度,由多家全球和本地参与者组成。目前主导市场的一些公司是梯瓦制药、辉瑞、葛兰素史克、Alliance Pharma、Piramal Healthcare UK Limited。

主要玩家

  1. Teva Pharmaceuticals

  2. GlaxoSmithKline

  3. Piramal Healthcare UK Limited

  4. Pfizer

  5. Alliance Pharma

*Disclaimer: Major Players sorted in no particular order

Hydroxyzine Imine Market

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Population with Allergic Reaction

      2. 4.2.2 Rise in Geriatric Population

      3. 4.2.3 Increasing Prevalence of Anxiety Disorders

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects associated with the Medication

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Dosage Form

      1. 5.1.1 Tablets

      2. 5.1.2 Capsules

      3. 5.1.3 Injection

      4. 5.1.4 Syrup

    2. 5.2 By Indication Type

      1. 5.2.1 Histamine-Mediated Pruritus

      2. 5.2.2 Urticaria

      3. 5.2.3 Atopic Contact Dermatoses

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Teva Pharmaceuticals

      2. 6.1.2 Pfizer

      3. 6.1.3 GlaxoSmithKline

      4. 6.1.4 Alliance Pharma

      5. 6.1.5 Piramal Healthcare UK Limited

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

从 2018 年到 2028 年研究了羟嗪亚胺市场。

未来 5 年,羟嗪亚胺市场的复合年增长率为 5.1%。

亚太地区在 2018 年至 2028 年期间的复合年增长率最高。

北美在 2021 年的份额最高。

Piramal Healthcare UK Limited、Alliance pharma PLC、Pfizer, Inc、GSK plc、Teva Pharmaceuticals 是在羟嗪亚胺市场运营的主要公司。

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!